{"id":893064,"date":"2025-10-07T07:03:16","date_gmt":"2025-10-07T11:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/"},"modified":"2025-10-07T07:03:16","modified_gmt":"2025-10-07T11:03:16","slug":"enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/","title":{"rendered":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek<\/b><b>\u2122<\/b><b> 2025<\/b><\/p>\n<p>WATERTOWN, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com%2F&amp;esheet=54333909&amp;newsitemid=20251007604798&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=9b0638728baa2a337c434372ac216c95\">Enanta Pharmaceuticals, Inc.<\/a> (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it\u2019s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek\u2122 2025 being held October 19 &#8211; 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia.<\/p>\n<p>\nDetails of the presentations are as follows:<\/p>\n<p><b><i>Zelicapavir:<\/i><\/b><\/p>\n<p><span class=\"bwuline\">Rapid-Fire Presentation<br \/>\n<br \/><\/span><b>Title: \u201c<\/b><i>Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age\u201d<br \/>\n<br \/><\/i><b>Date: <\/b>Monday, October 20, 2025<br \/>\n<br \/><b>Time: <\/b>12:35 PM &#8211; 12:40 PM EDT<br \/>\n<br \/><b>Presentation Number: <\/b>135<br \/>\n<br \/><b>Session:<\/b> Pediatric Respiratory Virus<br \/>\n<br \/><b>Location: <\/b>Poster Hall B4-B5 &#8211; Arena 2<br \/>\n<br \/><b>Presenter: <\/b>Dr. Christopher E. Harris<\/p>\n<p><span class=\"bwuline\">Poster<br \/>\n<br \/><\/span><b>Title: <\/b><i>\u201cZelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age\u201d<br \/>\n<br \/><\/i><b>Date<\/b>: Monday, October 20, 2025<br \/>\n<br \/><b>Time<\/b>: 12:15 PM &#8211; 1:30 PM EDT<br \/>\n<br \/><b>Poster Number:<\/b> 523<br \/>\n<br \/><b>Session: <\/b>Pediatric Viral Studies<br \/>\n<br \/><b>Location<\/b>: Poster Hall B4-B5<br \/>\n<br \/><b>Presenter<\/b>: Dr. Christopher E. Harris<\/p>\n<p><b><i>EDP-323:<\/i><\/b><\/p>\n<p><span class=\"bwuline\">Oral Presentation<br \/>\n<br \/><\/span><b>Presentation Title: <i>\u201c<\/i><\/b><i>EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge\u201d<br \/>\n<br \/><\/i><b>Date: <\/b>Monday, October 20, 2025<br \/>\n<br \/><b>Time: <\/b>4:15 PM &#8211; 4:27 PM EDT<br \/>\n<br \/><b>Presentation Number: <\/b>235<br \/>\n<br \/><b>Session: <\/b>New Anti-Infective Agents<br \/>\n<br \/><b>Location: <\/b>B213-B214<br \/>\n<br \/><b>Presenter: <\/b>Dr. John P. DeVincenzo<\/p>\n<p><span class=\"bwuline\">Poster Presentation<br \/>\n<br \/><\/span><b>Poster Title: <\/b><i>\u201cPost-Exposure Prophylaxis (PEP) of Respiratory Syncytial Virus (RSV) Infection After High-Inoculum RSV Human Challenge: Analysis of a Randomized Double-Blind, Placebo-Controlled Trial of EDP-323, an Oral, Non-Nucleoside Polymerase Inhibitor Antiviral\u201d<br \/>\n<br \/><\/i><b>Date: <\/b>Wednesday, October 22, 2025<br \/>\n<br \/><b>Time: <\/b>12:15 PM &#8211; 1:30 PM EDT<br \/>\n<br \/><b>Poster Number: <\/b>2181<br \/>\n<br \/><b>Session: <\/b>Virology<br \/>\n<br \/><b>Location: <\/b>Poster Hall B4-B5<br \/>\n<br \/><b>Presenter: <\/b>Dr. John P. DeVincenzo<\/p>\n<p>\nPosters will be available to view on the conference platform during the conference and on the Company\u2019s website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.enanta.com%2Fscience%2F%23publications&amp;esheet=54333909&amp;newsitemid=20251007604798&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=023b67687baa07213d21b6b63a5a1da2\">here<\/a> after presentations. Further information about IDWeek\u2122 2025 can be found <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fidweek.org&amp;esheet=54333909&amp;newsitemid=20251007604798&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=eabc13bb79cd8baf48b02164f5e38127\">here<\/a>.<\/p>\n<p><b>About Enanta Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta\u2019s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.<\/p>\n<p>\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). A portion of Enanta\u2019s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta\u2019s operations.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20251007604798\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20251007604798\/en\/<\/a><\/span><\/p>\n<p><b>Media and Investors Contact<br \/>\n<\/b><br \/>Jennifer Viera<br \/>\n<br \/>617-744-3848<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jviera@enanta.com\">jviera@enanta.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical Health Infectious Diseases Other Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20251007604798\/en\/1475183\/3\/Enanta_RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it\u2019s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek\u2122 2025 being held October 19 &#8211; 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia. Details of the presentations are as follows: Zelicapavir: Rapid-Fire Presentation Title: \u201cZelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893064","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it\u2019s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek\u2122 2025 being held October 19 &#8211; 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia. Details of the presentations are as follows: Zelicapavir: Rapid-Fire Presentation Title: \u201cZelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened &hellip; Continue reading &quot;Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T11:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025\",\"datePublished\":\"2025-10-07T11:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/\"},\"wordCount\":562,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/\",\"name\":\"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-10-07T11:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 - Market Newsdesk","og_description":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor, and EDP-323, it\u2019s oral, once-daily L-protein inhibitor, both in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek\u2122 2025 being held October 19 &#8211; 22, 2025 virtually and at the Georgia World Congress Center in Atlanta, Georgia. Details of the presentations are as follows: Zelicapavir: Rapid-Fire Presentation Title: \u201cZelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened &hellip; Continue reading \"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-07T11:03:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025","datePublished":"2025-10-07T11:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/"},"wordCount":562,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/","name":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-10-07T11:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20251007604798r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-for-the-treatment-of-respiratory-syncytial-virus-rsv-at-idweek-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek\u2122 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893064"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893064\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}